Imunon, Inc. (IMNN): who owns it and who trades it
As of Nov 16, 2026, IMNN insiders reported 6 open-market sales worth $38.1K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Susan Eylward (General Counsel and Corp), with $38.1K.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
In the last 12 months, IMNN insiders reported $0 of open-market purchases and $38.1K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 31, 2026 | Susan Eylward | General Counsel and Corp | Sale | 2,525 | $1.56 | $3.9K | Form 4 |
| Aug 17, 2026 | Susan Eylward | General Counsel and Corp | Sale | 2,449 | $1.63 | $4K | Form 4 |
| Aug 3, 2026 | Susan Eylward | General Counsel and Corp | Sale | 2,541 | $1.57 | $4K | Form 4 |
| Jul 20, 2026 | Susan Eylward | General Counsel and Corp | Sale | 2,150 | $1.78 | $3.8K | Form 4 |
| Jul 6, 2026 | Susan Eylward | General Counsel and Corp | Sale | 920 | $1.88 | $1.7K | Form 4 |
| Jun 29, 2026 | Susan Eylward | General Counsel and Corp | Sale | 11,800 | $1.75 | $20.6K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Susan Eylward | General Counsel and Corp Sec | – | $38.1K | Aug 31, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
IMNN short interest
Low short interest. 3.8% of IMNN shares are sold short: about 1 share in 26. Over the last 12 reports the number of shares short went up 47%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 215,645 IMNN shares were sold short, 3.8% of the shares outstanding, up 245.8% from the report before. At the average daily volume of 144,672 shares, buying them all back would take about 1.5 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 215,645 | 3.84% | +246% | 144,672 | 1.5 |
| Oct 15, 2026 | 62,366 | 1.11% | -64% | 92,780 | 1.0 |
| Sep 30, 2026 | 173,197 | 3.09% | -11% | 142,353 | 1.2 |
| Sep 15, 2026 | 193,639 | 3.45% | +114% | 154,079 | 1.3 |
| Aug 31, 2026 | 90,383 | 1.61% | -20% | 64,981 | 1.4 |
| Aug 14, 2026 | 112,958 | 2.01% | -25% | 44,668 | 2.5 |
| Jul 31, 2026 | 150,203 | 3.83% | +717% | 395,291 | 1.0 |
| Jul 15, 2026 | 18,395 | 0.47% | -64% | 31,422 | 1.0 |
| Jun 30, 2026 | 50,969 | 1.30% | -34% | 94,343 | 1.0 |
| Jun 15, 2026 | 77,034 | 1.96% | +34% | 49,682 | 1.6 |
| May 29, 2026 | 57,617 | 1.47% | -61% | 64,055 | 1.0 |
| May 15, 2026 | 146,860 | 3.74% | -6% | 41,038 | 3.6 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Imunon company events
Imunon filed 15 reports on Form 8-K in the last 12 months, 6 of them about an important change (leadership). The latest was on Oct 27, 2026.
- Oct 27, 2026AnnouncementImunon, Inc. made available an investor presentation, which the Company expects to use in connection with investor calls and/or conferences. Filing
- Oct 21, 2026AgreementImunon, Inc. entered into an Asset Purchase Agreement with VoxelDox Therapeutics, Inc., pursuant to which the Company agreed to sell to VoxelDox the Company’s assets relating to ThermoDox®, a heat-activated liposomal formulation of doxorubicin, including related trademarks, regulatory filings… Filing
- Sep 29, 2026AgreementAs previously reported, on June 2, 2026, Imunon, Inc. entered into a securities purchase agreement with Streeterville Capital, LLC, providing for the issuance and sale by the Company, and the purchase by the Investor, of (i) 250 shares of the Company’s Series A Preferred Stock, par value $0.01 per… Filing
- Aug 11, 2026LeadershipThe Compensation Committee and the Board of Directors of Imunon, Inc., as applicable, approved compensatory programs for certain executive officers, pursuant to which such executive officers may elect to receive a percentage of their base salary in the form of shares of common stock and will… Filing
- Aug 11, 2026ResultsReleased financial results. Filing
- Jun 30, 2026LeadershipJeffrey Church informed Imunon, Inc. of his intent to retire from the position of interim Chief Financial Officer (a position he has held since January of 2026), effective July 1, 2026. Filing
- Jun 16, 2026LeadershipAt the 2026 Annual Meeting of Stockholders of Imunon, Inc. held on June 16, 2026, the Company’s stockholders approved an amendment to the IMUNON, Inc. 2018 Stock Incentive Plan, which amendment was approved by the Company’s board of directors on February 27, 2026. Filing
- Jun 4, 2026AgreementImunon, Inc. entered into a securities purchase agreement with Streeterville Capital, LLC, providing for the issuance and sale by the Company, and the purchase by the Investor, of (i) 250 shares of the Company’s Series A Preferred Stock, par value $0.01 per share, at a price of $10,000 per share… Filing
- May 12, 2026ResultsReleased financial results. Filing
- May 4, 2026LeadershipCompensatory Arrangements of Certain Officers. Filing
- Mar 31, 2026ResultsReleased financial results. Filing
- Mar 23, 2026AnnouncementImunon, Inc. filed a prospectus supplement to register an additional $7 million of shares of the Company’s common stock, par value $0.01 per share, issuable pursuant to the At the Market Offering Agreement, dated as of May 25, 2022, as amended by Amendment No. 1 to At the Market Offering Agreement… Filing
- Feb 5, 2026LeadershipKhursheed Anwer informed Imunon, Inc. of his intent to retire as Executive Vice President and Chief Scientific Officer from the Company, and Dr. Anwer’s employment with the Company will end, effective February 20, 2026. Filing
- Jan 7, 2026LeadershipImunon, Inc. announced that Kimberly Graper, its interim Chief Financial Officer, will be resigning from her role effective January 14, 2026. Filing
- Dec 31, 2025AgreementImunon, Inc., a Delaware corporation, entered into a Securities Purchase Agreement with a single healthcare-focused institutional investor for a registered direct offering of (i) 330,000 shares of its common stock, par value $0.01 per share, (ii) pre-funded warrants in lieu of Shares, to the extent… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Imunon financials
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named IMNN in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Armistice Capital, LLC | 13G/A | 5.0% |
| Nov 16, 2026 | Armistice Capital, LLC | 13G/A | 5.0% |
Questions about Imunon, Inc. (IMNN) stock
Are IMNN insiders buying or selling?
In the last 12 months, IMNN insiders reported no open-market purchases and 6 sales worth $38.1K. The latest trade was on Aug 31, 2026. See every trade.
What is the short interest in IMNN?
As of Oct 30, 2026, 215,645 IMNN shares were sold short, 3.8% of the shares outstanding, up 245.8% from the report before. At the average daily volume of 144,672 shares, buying them all back would take about 1.5 trading days (days to cover). See the history.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.